Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VIA Pharmaceuticals, Inc. (VIAP)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
20.5
|
M
| |
|
|
| Market cap: |
|
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($7.7)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Jul-01-06 | Dec-31-05 | Jul-01-05 |
| Revenues | 1.8 | 6.1 | 11.8 | 10.7 | 5.7 | 4.0 | 16.0 | 3.4 |
| Revenue growth | -70.0% | -48.7% | 10.7% | 86.6% | -64.3% | 16.4% | 140.1% | 2.0% |
| Cost of goods sold | 4.2 | 7.2 | 8.7 | 7.9 | 2.5 | 0.8 | 31.9 | 0.8 |
| Gross profit | -2.4 | -1.1 | 3.1 | 2.8 | 3.2 | 3.2 | -15.9 | 2.6 |
| Gross margin | -131.3% | -18.9% | 26.7% | 26.3% | 56.1% | 79.4% | -99.0% | 76.0% |
| Research and development | | | | | | 67.6 | | 58.0 |
| General and administrative | 4.1 | 7.2 | 8.7 | 7.9 | 2.5 | 33.5 | 3.9 | 27.3 |
| EBIT | -5.9 | -13.3 | -20.5 | -22.3 | -8.2 | -101.8 | -19.8 | -85.9 |
| EBIT margin | -325.4% | -218.9% | -173.3% | -209.5% | -143.9% | -2554.7% | -123.3% | -2511.4% |
| Pre-tax income | -9.6 | -21.0 | -20.3 | -21.8 | -8.6 | -124.9 | -19.7 | -109.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -9.6 | -21.0 | -20.3 | -21.8 | -8.6 | -125.4 | -19.7 | -109.5 |
| Net margin | -528.3% | -346.5% | -171.8% | -204.7% | -150.9% | -3147.2% | -123.1% | -3200.7% |
| |
| Diluted EPS | ($0.47) | ($1.05) | ($1.03) | ($2.24) | ($19.81) | | ($1.16) | |
| Shares outstanding (diluted) | 20.4 | 19.9 | 19.6 | 9.7 | 0.4 | | 17.0 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|